<prompt> Answer this question truthfullyWhat is the purpose of clinical investigations involving second generation NS3NS4A protease inhibitors and NS5A inhibitors in relation to HCV treatment regimens?  <response>: <reason> Clinical investigations involving second generation NS3NS4A protease inhibitors and NS5A inhibitors are being conducted to develop HCV treatment regimens that do not require interferonribavirin administration. Interferonribavirin therapy has been the standard treatment for HCV for many years, but it can cause significant side effects and is not always effective. Second generation NS3NS4A protease inhibitors and NS5A inhibitors are a newer class of drugs that can be used in combination with other medications to treat HCV. By developing treatment regimens that do not require interferonribavirin, researchers hope to improve treatment outcomes and reduce the burden of side effects for patients with HCV. 